Literature DB >> 29472154

Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.

Imke Satzger1, Philipp Ivanyi2, Florian Länger3, Hans-Heinrich Kreipe4, Katrin Schaper-Gerhardt5, Gernot Beutel6, Markus Cornberg7, Ralf Gutzmer8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29472154     DOI： 10.1016/j.ejca.2018.01.063

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  12 in total

Review 1.  A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.

Authors:  Crescens Tiu; Rajiv Shinde; Abhijit Pal; Andrea Biondo; Alex Lee; Nina Tunariu; Shaman Jhanji; Vimal Grover; Kate Tatham; Pascale Gruber; Udai Banerji; Johann S De Bono; Emma Nicholson; Anna R Minchom; Juanita S Lopez
Journal:  J Immunother Precis Oncol       Date:  2021-09-07

2.  Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.

Authors:  Atsumasa Kurozumi; Hidenori Takahashi; Takayasu Watanabe; Yoshinobu Iwasaki
Journal:  Thorac Cancer       Date:  2021-03-30       Impact factor: 3.500

Review 3.  Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.

Authors:  Masood Sadaat; Sekwon Jang
Journal:  J Immunother Cancer       Date:  2018-06-05       Impact factor: 13.751

4.  Hematologic Complications of Immune Checkpoint Inhibitors.

Authors:  Elizabeth J Davis; Joe-Elie Salem; Arissa Young; Jennifer R Green; P Brent Ferrell; Kristin K Ancell; Benedicte Lebrun-Vignes; Javid J Moslehi; Douglas B Johnson
Journal:  Oncologist       Date:  2019-02-28

5.  Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.

Authors:  Roberta Noseda; Raffaela Bertoli; Laura Müller; Alessandro Ceschi
Journal:  J Immunother Cancer       Date:  2019-05-02       Impact factor: 13.751

6.  Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.

Authors:  James Kalmuk; Jon Puchalla; Gong Feng; Anshu Giri; John Kaczmar
Journal:  Cancers Head Neck       Date:  2020-02-03

7.  Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.

Authors:  Junling Zhuang; Jianhua Du; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-03       Impact factor: 3.500

8.  Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.

Authors:  Adeel Masood; Ahsan Wahab; Tanya Clifford; Eric J Weaver; Hamid Ehsan; Walid El Ayass
Journal:  Clin Case Rep       Date:  2021-12-05

Review 9.  [Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events].

Authors:  Junling Zhuang; Jingting Zhao; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Wei Qiu; Xiaoyan Si; Li Zhang; Yue Li; Xiaowei Liu; Hanping Wang; Daobin Zhou; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

10.  Encephalitis Associated With Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitors: An Unfamiliar Spin-Off.

Authors:  Ghulam Ghous; Hafiz Muhammad Hassan Shoukat; Zahid Ijaz Tarar; Muhammad Usman Zafar; Joseph W McGreevy
Journal:  Cureus       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.